Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. - Wikidata - awgldk - TriplyDB

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

http://www.wikidata.org/entity/Q37398815

about

Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.A current review of targeted therapeutics for ovarian cancer.Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma.Update on aurora kinase inhibitors in gynecologic malignancies.Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.Update on Aurora Kinase Targeted Therapeutics in Oncology.Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells.Aurora kinase inhibitors as anticancer molecules.Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3 Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion Novel strategies for reversing platinum resistance.Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.JAK2 inhibition for the treatment of hematologic and solid malignancies.The Aurora kinase inhibitors in cancer research and therapy.Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors.Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks.RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.

P2860

Q21245716-FFF06623-B68A-4A44-BED7-78DD00884F4F Q24295146-922EBD74-27C5-42A1-B0A5-23EC022D4460 Q28818608-0F5ACB0E-2DF2-4373-BFD7-339FBBAD152F Q30405442-30946176-7011-4DB7-AD98-FF97DF489B0F Q33580998-6EEE10A7-1F0B-4597-82D9-A17F4D720DFB Q33932460-7BC6DCF1-9B81-4967-9801-9F9200FB93CE Q33942098-975C5D06-6D0E-4D3E-85C6-E41BBF09483F Q34576017-E14109F0-84E5-4F9D-BBAA-1EF78524E7FF Q34632923-AABA12C5-165E-4556-8862-CCD53762B047 Q34941504-58ECD65E-E0D2-4664-B544-96BBC45E4584 Q35666453-86AD8D5E-34EF-4935-99A8-B9ECE59C9056 Q35850203-A2334C77-993C-4309-A174-63F10C969D24 Q36289893-BFA8B2A5-CAA4-4A62-844C-326C0E82BC6A Q36359684-A7080094-4804-4247-9831-463CE17BF567 Q36700778-B85391B8-5E70-45AB-9CA7-0D0BBB42CB3F Q36807632-E6FF228B-955F-4CF1-8164-DF47B1775FB5 Q37461061-EB63A31A-7FF6-498A-86E2-579BA369C41C Q37873924-F3705EF6-304D-4BE9-A6CF-E1A872F2CA4E Q38001733-58E2D793-98FB-45EC-9352-A10BF53C50FD Q38756932-110F276D-8069-4384-9630-AF201131CC70 Q39194457-7720155B-B3B6-4D58-9D02-D446EA627B17 Q39198408-D1387454-AC01-441C-95BA-1CBF6A9D6E19 Q39471062-77424365-7A75-4D4F-9A92-DBF728588A96 Q39596870-49DE1729-86C3-4935-92F6-C8BAA5836AEF Q42562915-56EC9C51-2DF9-46C7-89E0-E1E57484D00D Q43096508-241E235A-B679-4AD0-9A57-AF16ECE7F125 Q49025576-56DC9D0A-AE9F-4ADA-AF52-03FA543A49E1 Q53277143-53A34F62-7326-441A-B311-4001D93F4803

P2860

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

http://www.wikidata.org/entity/Q37398815

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

@en

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

@nl

type

label

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

@en

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

@nl

prefLabel

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

@en

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

@nl

P1433

Q37398815-F3E5AA9E-FE1E-4F57-9833-C33B17A010BE

P1476

Q37398815-31F2FFC6-61D4-4A97-B7A8-083EFBB6C669

P2093

Q37398815-04A0A573-E19A-4155-BD78-690A5E5D683D

Q37398815-0C637332-5E66-4A18-89D9-64CAD75386AB

Q37398815-35A0B13E-B169-4E32-BCA3-2E7F053DA47A

Q37398815-42DB832F-CCB7-4B27-9046-F995434AE2D7

Q37398815-52CE5A62-1D28-4995-8AAF-4C657682238F

Q37398815-9EB42B36-9FE9-45E3-9313-067D2778435C

Q37398815-A3E416E8-3493-4BEF-868E-CB3E1EF2413D

Q37398815-AA23DDA9-C96C-43BC-AF5E-F6D208BAFCAC

Q37398815-BB452A22-3A51-4837-9C05-61429ECAD7D8

Q37398815-C41681D6-6C3A-47AB-966C-0FEBCBAFC172

P2860

Q37398815-0159FDF2-84AF-4D26-82DB-21C46B168C1B

Q37398815-0AB3842F-CAE0-4EED-8268-0772978E8A88

Q37398815-0E8CE6CC-992F-4ADC-AC0D-EF663D38902A

Q37398815-1035A4A4-691B-4B93-8480-24B0C97A8D23

Q37398815-1CBFF602-15A8-483D-8A2D-D4263D657E09

Q37398815-23D4CA15-BB18-4C51-AEE9-B74A82D59E31

Q37398815-2E1F859B-AE61-436D-8867-4096A038F5F2

Q37398815-2E6EDF48-0A72-4632-9CE8-25C610F7233B

Q37398815-37851185-8784-4CB1-9B51-09CAD1166719

Q37398815-391BEC6C-56FE-4264-8221-02AA3AC59B6C

P304

Q37398815-8C1591B7-CB06-44D4-B89F-47926BC8A658

P31

Q37398815-C71309A6-83C1-4221-9B28-961D25593E47

P356

Q37398815-9976BD28-C77D-4182-A017-E8F97EFCC149

P407

Q37398815-34DE9F0E-AA06-450B-A75B-BA2770F1D136

P433

Q37398815-C1DE36D1-890F-4F39-A3F1-05AF921B5529

P478

Q37398815-C98A2BC3-5E69-4276-94D0-E486DB3B9855

P50

Q37398815-1B75E609-C85A-4FBF-AB44-1F7EECBC191E

Q37398815-3B44805A-BEA0-47A9-A870-84C70732AD22

Q37398815-F3CC2819-7B31-467C-80F3-331B0678504E

P577

Q37398815-1E2CC3E5-1BD2-4640-A6A4-FD20C393AB35

P5875

Q37398815-787C879B-5CCE-4A95-9A25-8C998F7990F7

P698

Q37398815-E4734E14-98C4-4D5A-A1ED-E287A5E67A7A

P921

Q37398815-3370CDFE-C625-4F49-9170-9274130AC93F

P932

Q37398815-C6E0688E-2605-45F6-80F5-7FCA83DB6233

P356

1078-0432.CCR-07-4922

P1433

Clinical Cancer Research

P1476

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth

@en

P2093

Alpa M Nick

http://www.w3.org/2001/XMLSchema#string

Anand Immaneni

http://www.w3.org/2001/XMLSchema#string

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Aparna A Kamat

http://www.w3.org/2001/XMLSchema#string

Charles N Landen

http://www.w3.org/2001/XMLSchema#string

Chunhua Lu

http://www.w3.org/2001/XMLSchema#string

Lingegowda S Mangala

http://www.w3.org/2001/XMLSchema#string

Liz Y Han

http://www.w3.org/2001/XMLSchema#string

Mian M K Shahzad

http://www.w3.org/2001/XMLSchema#string

Michael J Gray

http://www.w3.org/2001/XMLSchema#string

P2860

Aurora-A kinase interacting protein (AIP), a novel negative regulator of human Aurora-A kinase

Significance analysis of microarrays applied to the ionizing radiation response

The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection

Cancer statistics, 2007

Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.

The Aurora kinases: role in cell transformation and tumorigenesis.

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

P304

5437-5446

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-4922

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Guillermo Armaiz-Pena

Diane C Bodurka

Kwong-Kwok Wong

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23231781

http://www.w3.org/2001/XMLSchema#string

P698

18765535

http://www.w3.org/2001/XMLSchema#string

P921

P932

2766914

http://www.w3.org/2001/XMLSchema#string